JP5752789B2 - Ｈｉｖ成熟阻害剤としての修飾ｃ−３ベツリン酸誘導体 - Google Patents
Ｈｉｖ成熟阻害剤としての修飾ｃ−３ベツリン酸誘導体 Download PDFInfo
- Publication number
- JP5752789B2 JP5752789B2 JP2013513339A JP2013513339A JP5752789B2 JP 5752789 B2 JP5752789 B2 JP 5752789B2 JP 2013513339 A JP2013513339 A JP 2013513339A JP 2013513339 A JP2013513339 A JP 2013513339A JP 5752789 B2 JP5752789 B2 JP 5752789B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- cyclopenta
- coor
- pentamethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *OC(c1ccccc1)=O Chemical compound *OC(c1ccccc1)=O 0.000 description 3
- HCXUOUGXYJPDST-XNNWPPRGSA-N CC(C)([C@@H]1CC2)C(c3ccc(C(O)=O)c(Cl)c3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c3ccc(C(O)=O)c(Cl)c3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 HCXUOUGXYJPDST-XNNWPPRGSA-N 0.000 description 3
- IFLFEIAIYVETFD-VJBSNJLKSA-N CC(C)([C@@H]1CC2)C(OS(C(F)(F)F)(=O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(COC(c1ccccc1)=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(OS(C(F)(F)F)(=O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(COC(c1ccccc1)=O)CC2 IFLFEIAIYVETFD-VJBSNJLKSA-N 0.000 description 1
- LONIAVLTQYVYQE-SSVRXCMJSA-N CC(C)([C@@H]1CC2)C(OS(C(F)(F)F)(=O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(OCc1ccccc1)=O Chemical compound CC(C)([C@@H]1CC2)C(OS(C(F)(F)F)(=O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(OCc1ccccc1)=O LONIAVLTQYVYQE-SSVRXCMJSA-N 0.000 description 1
- VIXQOXMDSUBYRP-VOJFVTJTSA-N CC(C)([C@@H]1CC2)C(c(cc3)cc(F)c3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)cc(F)c3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 VIXQOXMDSUBYRP-VOJFVTJTSA-N 0.000 description 1
- ZKHRHUDBEOGJKP-UBVMEDRPSA-N CC(C)([C@@H]1CC2)C(c(cc3)cc(F)c3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21C(O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)cc(F)c3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21C(O)=O ZKHRHUDBEOGJKP-UBVMEDRPSA-N 0.000 description 1
- RYJSSLRXTYVASV-VOJFVTJTSA-N CC(C)([C@@H]1CC2)C(c(cc3)cc(O)c3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)cc(O)c3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 RYJSSLRXTYVASV-VOJFVTJTSA-N 0.000 description 1
- IRBHQSJDISMZRR-RPAAZHKCSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(Cl)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(OCc1ccccc1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(Cl)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(OCc1ccccc1)=O IRBHQSJDISMZRR-RPAAZHKCSA-N 0.000 description 1
- DNBYVTKKNZIMLW-TVJWCRJGSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(NS(C)(=O)=O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(NS(C)(=O)=O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(O)=O DNBYVTKKNZIMLW-TVJWCRJGSA-N 0.000 description 1
- QKAAVEAVZYEKIE-OKTKUWAQSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 QKAAVEAVZYEKIE-OKTKUWAQSA-N 0.000 description 1
- OJXAUTDCWNZCLO-MIYVCLLESA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3NC(CCC(O)=O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21C(O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3NC(CCC(O)=O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21C(O)=O OJXAUTDCWNZCLO-MIYVCLLESA-N 0.000 description 1
- RIXYGFSCYAEKKT-SLLAXXTQSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3S(C)(=O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3S(C)(=O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(O)=O RIXYGFSCYAEKKT-SLLAXXTQSA-N 0.000 description 1
- ILGQKWCERDYWAC-VOJFVTJTSA-N CC(C)([C@@H]1CC2)C(c(ccc(C(O)=O)c3)c3F)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(ccc(C(O)=O)c3)c3F)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 ILGQKWCERDYWAC-VOJFVTJTSA-N 0.000 description 1
- ILGQKWCERDYWAC-XNNWPPRGSA-N CC(C)([C@@H]1CC2)C(c(ccc(C(O)=O)c3)c3F)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(ccc(C(O)=O)c3)c3F)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 ILGQKWCERDYWAC-XNNWPPRGSA-N 0.000 description 1
- OTKAMDGGHKJIGH-IYFAHJLCSA-N CC(C)([C@@H]1CC2)C(c3cc(-c4n[nH]nn4)ccc3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(O)=O Chemical compound CC(C)([C@@H]1CC2)C(c3cc(-c4n[nH]nn4)ccc3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(O)=O OTKAMDGGHKJIGH-IYFAHJLCSA-N 0.000 description 1
- CBGIGRZNUSJXHN-DGFPWVBQSA-N CC(C)([C@@H]1CC2)C(c3cc(C(O)=O)n[o]3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)C1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c3cc(C(O)=O)n[o]3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)C1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CO)CC2 CBGIGRZNUSJXHN-DGFPWVBQSA-N 0.000 description 1
- VOBAPTBAJDSMFV-SLLAXXTQSA-N CC(C)([C@@H]1CC2)C(c3cc(NS(C)(=O)=O)ccc3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(O)=O Chemical compound CC(C)([C@@H]1CC2)C(c3cc(NS(C)(=O)=O)ccc3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(O)=O VOBAPTBAJDSMFV-SLLAXXTQSA-N 0.000 description 1
- JPNIHRUJLQVTLS-BORONXEDSA-N CC(C)([C@@H]1CC2)C(c3ccc(/C=C/C(O)=O)cc3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(O)=O Chemical compound CC(C)([C@@H]1CC2)C(c3ccc(/C=C/C(O)=O)cc3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(O)=O JPNIHRUJLQVTLS-BORONXEDSA-N 0.000 description 1
- AMDLFQTWXJDEPS-CNYWEUNBSA-N CC(C)([C@@H]1CC2)C(c3ccc(C(O)=O)c(Cl)c3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(O)=O Chemical compound CC(C)([C@@H]1CC2)C(c3ccc(C(O)=O)c(Cl)c3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(O)=O AMDLFQTWXJDEPS-CNYWEUNBSA-N 0.000 description 1
- PMSBJRSKUCXXTO-LRAKCVRGSA-N CC(C)([C@@H]1CC2)C(c3ccc(C4(CC4)C(O)=O)cc3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21C(O)=O Chemical compound CC(C)([C@@H]1CC2)C(c3ccc(C4(CC4)C(O)=O)cc3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21C(O)=O PMSBJRSKUCXXTO-LRAKCVRGSA-N 0.000 description 1
- XTVQPZUKCIKKGW-JKOHZOSMSA-N CC(C)([C@@H]1CC2)C(c3cccc(S(NC)(=O)=O)c3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21C(O)=O Chemical compound CC(C)([C@@H]1CC2)C(c3cccc(S(NC)(=O)=O)c3)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21C(O)=O XTVQPZUKCIKKGW-JKOHZOSMSA-N 0.000 description 1
- AQJIQMVLTLKQMX-JWTSRXDFSA-N CC(C)[C@H](CC1)[C@H]([C@H]2CC3)C1(CO)CC[C@@]2(C)[C@](C)(CC1)[C@H]3[C@]2(C)[C@@H]1C(C)(C)C(c(cc1)ccc1C(O)=O)=CC2 Chemical compound CC(C)[C@H](CC1)[C@H]([C@H]2CC3)C1(CO)CC[C@@]2(C)[C@](C)(CC1)[C@H]3[C@]2(C)[C@@H]1C(C)(C)C(c(cc1)ccc1C(O)=O)=CC2 AQJIQMVLTLKQMX-JWTSRXDFSA-N 0.000 description 1
- SVMWRLNUJOVLPB-BMSVDXQESA-N CCOC(c1n[o]c(C(C(C)(C)[C@@H]2CC3)=CC[C@]2(C)[C@@H](CC2)[C@]3(C)[C@@]3(C)C2[C@@H]([C@@H](CC2)C(C)=C)[C@@]2(COC(c2ccccc2)=O)CC3)c1)=O Chemical compound CCOC(c1n[o]c(C(C(C)(C)[C@@H]2CC3)=CC[C@]2(C)[C@@H](CC2)[C@]3(C)[C@@]3(C)C2[C@@H]([C@@H](CC2)C(C)=C)[C@@]2(COC(c2ccccc2)=O)CC3)c1)=O SVMWRLNUJOVLPB-BMSVDXQESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35133810P | 2010-06-04 | 2010-06-04 | |
| US61/351,338 | 2010-06-04 | ||
| PCT/US2011/038879 WO2011153315A1 (en) | 2010-06-04 | 2011-06-02 | Modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013527242A JP2013527242A (ja) | 2013-06-27 |
| JP2013527242A5 JP2013527242A5 (enExample) | 2014-07-17 |
| JP5752789B2 true JP5752789B2 (ja) | 2015-07-22 |
Family
ID=44627236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513339A Expired - Fee Related JP5752789B2 (ja) | 2010-06-04 | 2011-06-02 | Ｈｉｖ成熟阻害剤としての修飾ｃ−３ベツリン酸誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8754068B2 (enExample) |
| EP (1) | EP2576585B8 (enExample) |
| JP (1) | JP5752789B2 (enExample) |
| CN (1) | CN103038245B (enExample) |
| AR (1) | AR081637A1 (enExample) |
| BR (1) | BR112012030818A2 (enExample) |
| CA (1) | CA2801487C (enExample) |
| EA (1) | EA022393B1 (enExample) |
| ES (1) | ES2612452T3 (enExample) |
| MX (1) | MX2012013703A (enExample) |
| TW (1) | TW201201793A (enExample) |
| WO (1) | WO2011153315A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11090313B2 (en) | 2010-05-20 | 2021-08-17 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
| CN103037692B (zh) | 2010-05-20 | 2015-02-25 | 爱荷华大学研究基金会 | 用于抑制肌萎缩的方法 |
| ES2653847T3 (es) * | 2011-01-31 | 2018-02-09 | Viiv Healthcare Uk (No. 4) Limited | Triterpenoides C-17 y C-3 modificados con actividad inhibitoria contra maduración del VIH |
| CN103339141B (zh) * | 2011-01-31 | 2016-08-24 | 百时美施贵宝公司 | 作为hiv成熟抑制剂的c-3修饰的桦木酸衍生物的c-28胺 |
| US9295664B2 (en) | 2011-06-06 | 2016-03-29 | University Of Iowa Research Foundation | Methods for lowering blood glucose |
| ES2611727T3 (es) | 2011-09-21 | 2017-05-10 | VIIV Healthcare UK (No.5) Limited | Derivados de ácido betulínico novedosos con actividad antivírica |
| US8906889B2 (en) * | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| US8889854B2 (en) | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| WO2014105926A1 (en) | 2012-12-31 | 2014-07-03 | Hetero Research Foundation | Novel betulinic acid proline derivatives as hiv inhibitors |
| JP6186010B2 (ja) * | 2013-02-06 | 2017-08-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性を有するｃ−１９修飾トリテルペノイド類 |
| KR20150121712A (ko) * | 2013-02-25 | 2015-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | Hiv의 치료에 유용한 c-3 알킬 및 알케닐 개질된 베툴린산 유도체 |
| MA39374A1 (fr) | 2014-04-11 | 2018-06-29 | Viiv Healthcare Uk No 4 Ltd | Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle |
| WO2015195776A1 (en) | 2014-06-19 | 2015-12-23 | Bristol-Myers Squibb Company | Betulinic acid derivatives with hiv maturation inhibitory activity |
| US20170129916A1 (en) | 2014-06-26 | 2017-05-11 | Hetero Research Foundation | Novel betulinic proline imidazole derivatives as hiv inhibitors |
| BR112017009850A2 (pt) * | 2014-11-14 | 2018-01-16 | Viiv Healthcare Uk No 5 Ltd | composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto |
| WO2016077572A1 (en) * | 2014-11-14 | 2016-05-19 | Bristol-Myers Squibb Company | Extended betulinic acid analogs |
| RU2017118576A (ru) | 2014-11-14 | 2018-12-14 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | C-17-арил-замещённые аналоги бетулиновой кислоты |
| MA40886B1 (fr) | 2015-02-09 | 2020-03-31 | Hetero Research Foundation | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih |
| WO2016147099A2 (en) | 2015-03-16 | 2016-09-22 | Hetero Research Foundation | C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors |
| KR20180028534A (ko) | 2015-07-28 | 2018-03-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체 |
| RU2018105352A (ru) | 2015-07-28 | 2019-08-29 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Производные бетулина для предупреждения или лечения ВИЧ-инфекций |
| CN108368071A (zh) | 2015-09-24 | 2018-08-03 | 葛兰素史克知识产权第二有限公司 | 具有hiv成熟抑制活性的化合物 |
| CN108699103A (zh) | 2016-01-20 | 2018-10-23 | 葛兰素史克知识产权第二有限公司 | 具有hiv成熟抑制活性的羽扇烷类的胺衍生物 |
| AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| EP3478661A1 (en) * | 2016-06-30 | 2019-05-08 | ViiV Healthcare UK (No.5) Limited | Aza-substituted inhibitors of human immunodeficiency virus replication |
| EP3478703A1 (en) * | 2016-06-30 | 2019-05-08 | ViiV Healthcare UK (No.5) Limited | Triterpenoid inhibitors of human immunodeficiency virus replication |
| US10493070B2 (en) | 2016-06-30 | 2019-12-03 | Viiv Healthcare Uk (No. 5) Limited | Azadecalin derivatives as inhibitors of human immunodeficiency virus replication |
| WO2019207460A1 (en) | 2018-04-24 | 2019-10-31 | VIIV Healthcare UK (No.5) Limited | Compounds with hiv maturation inhibitory activity |
| PL237998B1 (pl) | 2018-05-28 | 2021-06-28 | Narodowy Inst Lekow | Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5962527A (en) | 1995-03-21 | 1999-10-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating cancers |
| US5869535A (en) | 1995-03-21 | 1999-02-09 | The Board Of Trustees Of The University Of Illinois | Method and composition for selectively inhibiting melanoma |
| US5679828A (en) * | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| ATE348839T1 (de) * | 1998-03-02 | 2007-01-15 | Univ North Carolina | Acylierte betulin- und dihydrobetulinderivate, ihre herstellung und verwendung |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| NZ538896A (en) * | 2002-09-26 | 2007-10-26 | Niigata University Of Pharmacy | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| EP1594885B8 (de) * | 2003-02-11 | 2009-03-25 | Novelix Pharmaceuticals, Inc. | Medikament zur wachstumsinhibierung von tumoren |
| WO2004089357A2 (en) | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| JP2007529544A (ja) * | 2004-03-17 | 2007-10-25 | パナコス ファーマシューティカルズ， インコーポレイテッド | ３−ｏ−（３’，３’−ジメチルスクシニル）ベツリン酸の製薬的な塩 |
| WO2005112929A2 (en) | 2004-05-20 | 2005-12-01 | Cornell Research Foundation, Inc. | Anti-hiv-1 activity of betulinol derivatives |
| TW200628161A (en) * | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| EP1986654A2 (en) * | 2006-02-21 | 2008-11-05 | Achillion Pharmaceuticals, Inc. | Substituted taraxastanes useful for treating viral infections |
| WO2008127364A2 (en) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
| US20110144069A1 (en) | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| US20090062243A1 (en) * | 2007-08-03 | 2009-03-05 | Advanced Life Sciences, Inc. | Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof |
| WO2009042166A1 (en) | 2007-09-25 | 2009-04-02 | Panacos Pharmaceuticals, Inc. | Liquid bevirimat dosage forms for oral administration |
| CA2714049A1 (en) | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | Novel 17.beta. lupane derivatives |
| WO2009114083A2 (en) | 2008-03-03 | 2009-09-17 | Panacos Pharmaceuticals, Inc. | Determinants of antiviral response |
| SI2271658T1 (sl) * | 2008-04-18 | 2017-03-31 | Reata Pharmaceuticals, Inc. | Antioksidantni modulatorji vnetja: C-17 homologirani derivati oleanolne kisline |
| KR20120138761A (ko) * | 2010-02-11 | 2012-12-26 | 글락소스미스클라인 엘엘씨 | 베툴린의 유도체 |
-
2011
- 2011-06-02 ES ES11726563.7T patent/ES2612452T3/es active Active
- 2011-06-02 CN CN201180038211.9A patent/CN103038245B/zh not_active Expired - Fee Related
- 2011-06-02 MX MX2012013703A patent/MX2012013703A/es active IP Right Grant
- 2011-06-02 JP JP2013513339A patent/JP5752789B2/ja not_active Expired - Fee Related
- 2011-06-02 EP EP11726563.7A patent/EP2576585B8/en not_active Not-in-force
- 2011-06-02 US US13/151,706 patent/US8754068B2/en not_active Expired - Fee Related
- 2011-06-02 CA CA2801487A patent/CA2801487C/en not_active Expired - Fee Related
- 2011-06-02 EA EA201270780A patent/EA022393B1/ru not_active IP Right Cessation
- 2011-06-02 BR BR112012030818A patent/BR112012030818A2/pt not_active IP Right Cessation
- 2011-06-02 WO PCT/US2011/038879 patent/WO2011153315A1/en not_active Ceased
- 2011-06-03 TW TW100119644A patent/TW201201793A/zh unknown
- 2011-06-03 AR ARP110101944A patent/AR081637A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013527242A (ja) | 2013-06-27 |
| EP2576585A1 (en) | 2013-04-10 |
| EA201270780A1 (ru) | 2013-04-30 |
| WO2011153315A1 (en) | 2011-12-08 |
| EA022393B1 (ru) | 2015-12-30 |
| CA2801487C (en) | 2017-12-05 |
| US20120142707A1 (en) | 2012-06-07 |
| AR081637A1 (es) | 2012-10-10 |
| US8754068B2 (en) | 2014-06-17 |
| TW201201793A (en) | 2012-01-16 |
| EP2576585B8 (en) | 2016-12-21 |
| ES2612452T3 (es) | 2017-05-17 |
| EP2576585B1 (en) | 2016-10-12 |
| MX2012013703A (es) | 2012-12-17 |
| CN103038245A (zh) | 2013-04-10 |
| BR112012030818A2 (pt) | 2019-09-24 |
| CA2801487A1 (en) | 2011-12-08 |
| CN103038245B (zh) | 2015-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5752789B2 (ja) | Ｈｉｖ成熟阻害剤としての修飾ｃ−３ベツリン酸誘導体 | |
| JP5755731B2 (ja) | Ｈｉｖ成熟阻害剤としての修飾ｃ−３ベツリン酸誘導体のｃ−２８アミド | |
| JP6186012B2 (ja) | Ｃ−３アルキルおよびアルケニル修飾ベツリン酸誘導体 | |
| JP6155285B2 (ja) | Ｈｉｖ成熟阻害活性のあるｃ−３シクロアルケニルトリテルペノイド | |
| JP6212545B2 (ja) | Ｈｉｖ成熟阻害活性を有するｃ−１７二環式アミンのトリテルペノイド | |
| AU2015346303A1 (en) | Oxolupene derivatives | |
| JP6620149B2 (ja) | 拡張ベツリン酸類似体 | |
| US10047118B2 (en) | C17-aryl substituted betulinic acid analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130205 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140527 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140527 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150421 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150520 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5752789 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |